Ahmed I Megahed

  • Citations Per Year
Learn More
Metastatic melanoma is a deadly disease with a 5-year survival rate lower than 20%. In 2011, ipilimumab, a fully humanized antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) was approved by the US Food and Drug Administration based on improved survival in a pivotal trial. CTLA4 is a molecule on cytotoxic T-lymphocytes that plays a(More)
This paper describes a new Artificial Neural Network (ANN) based digital differential protection scheme for generator stator winding protection. The scheme includes two Feedforward Neural Networks (FNNs). One ANN is used for fault detection and the other is used for internal fault classification. This design uses current samples from the line-side and the(More)
The approval of ipilimumab and inhibitors of the BRAF pathway for the treatment of melanoma has provided multiple therapeutic options for patients. Although these new agents improve survival compared with chemotherapy alone, the majority of patients will progress and will receive chemotherapy at some point in the course of their disease. Whether the(More)
  • 1